Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
about
Human brain myelination and amyloid beta deposition in Alzheimer's diseaseSelective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's diseaseImaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence ImagingDevelopment of positron emission tomography β-amyloid plaque imaging agentsEndogenous murine Aβ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice.Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's diseasePrecuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease.Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's diseaseAlzheimer disease models and human neuropathology: similarities and differencesA review of β-amyloid neuroimaging in Alzheimer's disease.Molecular imaging biomarkers for dementia with Lewy bodies: an update.Structural Magnetic Resonance Imaging Markers of Alzheimer's Disease and Its Retranslation to Rodent Models.Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's diseaseTracking Alzheimer's disease.Differentiating Alzheimer disease-associated aggregates with small molecules.Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's diseaseResilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients.PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease.Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines.Unveiling molecular events in the brain by noninvasive imaging.Probing small molecule binding to amyloid fibrils.Molecular brain imaging in the multimodality era.In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's diseaseIdentification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model.A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brainAutomated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI.Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease.Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent.Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseRetinal vascular biomarkers for early detection and monitoring of Alzheimer's disease.Tritium-labeled (E,E)-2,5-bis(4'-hydroxy-3'-carboxystyryl)benzene as a probe for β-amyloid fibrilsDevelopment and screening of contrast agents for in vivo imaging of Parkinson's disease.[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamolPET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's diseaseAstrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
P2860
Q22252428-F8697790-A231-4731-B404-94BF0F7B067DQ24633911-82988B1F-0341-4F6E-8164-F3F5A01F83E4Q26770766-9E945C60-E2FC-491B-9143-D19E442C9C11Q27012742-171BC560-4F8F-4AEC-ADA6-B18F649A377EQ27307747-5F4014C6-C03B-443C-AAF2-A3C20DEF4DA0Q27309046-70BCB350-7F44-495D-90C7-EC0D3D41FF36Q30426091-305EEFE2-10ED-4381-94DF-94FD6E20DD2AQ30436728-BEB8C8F2-431F-41E0-B60D-E4BFBBADFB36Q30497749-6A3BFA11-7A9B-4C94-8D17-B2C9DF1819DEQ30499574-8D616678-2005-414C-8F7A-25E619BAFBABQ30870063-9F7F98D4-3008-407A-B3F2-1146DCE1D58EQ30881333-D2DC39EC-F8E6-4971-9632-F8E2ED0544D7Q30996675-AFE2A4D1-750D-438C-BD0B-22AC592E495AQ31093609-0AAEDFAD-AE1D-4EB8-8B86-4F61D62AA76CQ31143998-AB94FDA3-8F04-465D-B7E4-81F12820A9CAQ33281339-B931BD81-A6E0-4C36-B418-2EBD41CF2B61Q33296123-472A6686-110E-4220-BAD1-1D7DE1214937Q33494855-65B9B17D-B464-48C6-AC7C-C6FA6EEA9C6AQ33895321-DD0EE4BD-7379-4086-A74B-D07906452D5BQ33925710-64AC1C4A-3EAD-4869-90B4-E4552C5D3B68Q33936595-36BA8ACB-F07B-43D3-9741-855F744158ABQ33970428-390A534B-B28F-48C1-9857-4180DB8BCF03Q33993315-7969F714-3BC5-43B3-9210-240CABD6F750Q34046040-6CB54629-50DC-4007-856E-2A5024206835Q34050053-28C1FED3-E311-43C7-83A2-1648969E2672Q34204125-F2F63C69-1398-492D-9E7D-E10EB5D3E179Q34295798-7823232F-D8A7-4DC8-A6A2-A65910D6D9D3Q34349078-6473D3DB-41F7-4D46-9CD1-0F82771AA39FQ34381799-42CBB4F7-B46E-4ECF-BBB0-22DF6880366CQ34538462-F8FD9106-FA91-4BE1-B743-88BBCBDDF2E7Q34572900-B1317A29-80A8-4546-934F-5DA3DB26AC52Q34584062-B91C1E4E-662C-46E7-A21E-D78BFF38439FQ34589414-0AC6749F-E655-4BC5-AE93-46389692028DQ34601458-1A5B9AAE-6AD2-4817-A0D6-778E66243AE9Q34625450-287D8F0F-6D7D-45BC-BBA7-851676D4976FQ34691754-1CC072E0-EA31-41E9-8A9C-EA2DB2BD9795Q35131160-D71AB149-BCD0-42A4-825B-DF8E3D25DCCFQ35546528-4B83F92A-9E3D-4C2F-B96E-1EC0034102B3Q35579225-54C63774-9FB0-4BB1-9724-2E02DB3450E7Q35582909-68C296FF-2461-4CE5-A8AA-610F276E92C6
P2860
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Binding of the positron emissi ...... not in transgenic mouse brain.
@en
Binding of the positron emissi ...... not in transgenic mouse brain.
@nl
type
label
Binding of the positron emissi ...... not in transgenic mouse brain.
@en
Binding of the positron emissi ...... not in transgenic mouse brain.
@nl
prefLabel
Binding of the positron emissi ...... not in transgenic mouse brain.
@en
Binding of the positron emissi ...... not in transgenic mouse brain.
@nl
P2093
P50
P1476
Binding of the positron emissi ...... not in transgenic mouse brain
@en
P2093
Brian J Lopresti
Chester A Mathis
Daniel P Holt
Eric E Abrahamson
Guo-feng Huang
Iliya M Lefterov
Julie C Price
Manik L Debnath
Milos D Ikonomovic
P304
10598-10606
P356
10.1523/JNEUROSCI.2990-05.2005
P407
P577
2005-11-01T00:00:00Z